RESULTS OF THE PHARMACOECONOMIC ANALYSIS OF THE USE OF A PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE FOR PREVENTION OF PNEUMOCOCCAL INFECTIONS IN CHILDREN DURING FIRST 5 YEARS OF LIFE IN THE RUSSIAN FEDERATION

• Main Authors: A.A. Baranov (Author), V.V. Omel'yanovskii (Author), N.I. Briko (Author), Yu.V. Lobzin (Author), L.S. Namazova-Baranova (Author), V.K. Tatochenko (Author), S.M. Kharit (Author), S.V. Sidorenko (Author), I.S. Koroleva (Author), A.E. Platonov (Author), G.Yu. Moisyak (Author), I.S. Krysanov (Author), O.I. Ivakhnenko (Author), F.M. Tsfasman (Author)
• Format: Book
• Published: Union of pediatricians of Russia, 2009-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

The article discusses the first results of a pharmacoeconomic analysis of the efficacy of using the Pneumococcal conjugated 7-valent vaccine (PCV7) for immunization of children aged 2 months to 5 years in Russia using techniques for modeling various approaches to cohort immunization. It shows clinical and economic efficacy of implementing routine immunization in children during first 5 years against pneumococcal infection using PCV7 given direct and indirect costs. It justifies the expediency of incorporating vaccination against pneumococcal infection in children aged 2 months up into the Russian National Immunization Schedule.Key words: pharmacoeconomic analysis, children during first 5 years of life, vaccination, pneumococcal conjugated 7-valent vaccine

Item Description

1727-5776
2500-3089